Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 4, 2008

View Archived Issues

Novel plant-derived vaccine found safe and immunogenic in lymphoma patients

Efalizumab shows efficacy in the treatment of head and neck psoriasis

Pfizer's PF-3084014 effectively reduces Abeta levels in guinea pigs and mice

Novel fluorene compounds neutralize Abeta-oligomer toxicity in preclinical studies

Upregulation of Hsp70 by KU-32 leads to a reduction of Tau phosphorylation in mice

Mayo Clinic initiates dosing in phase Ib clinical study of Nile's CD-NP in heart failure

Bristol-Myers proposes to acquire ImClone Systems

Novel NS5B polymerase inhibitors described in recent patents

Novel oncolytic agents reported in patent literature

Upstream and Makerere University to collaborate on animal testing of Leishmaniasis treatment

Seattle Genetics commences phase I trial for SGN-70 in healthy volunteers

FDA issues not approvable letter to Schering-Plough for sugammadex

FDA grants orphan drug designation to afamelanotide in erythropoietic porphyrias

E.U. grants approval to Actelion's Tracleer in mildly symptomatic PAH

Karo Bio reports positive results from phase IIb study with eprotirome in dyslipidemia

Labopharm launches once-daily tramadol in South Korea, Australia, Romania and Austria

Aegera initiates dosing in phase I/II clinical oncology study of AEG-35156

BioMS completes enrollment in phase III MAESTRO-03 clinical trial of dirucotide

FDA awards RegeneRx additional USD 136,000 for phase II trial of RGN-137 in EB

Gilead and Merck & Co. sign agreement for HIV medication Atripla in 12 countries

PYY(3-36) for obesity does not meet primary efficacy endpoint in phase II study

Wyeth reviews Q2 highlights

Patents reveal discovery of compounds for metabolic disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...